These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 35709810)

  • 1. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
    Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
    Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
    Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
    Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.
    Arbyn M; Smith SB; Temin S; Sultana F; Castle P;
    BMJ; 2018 Dec; 363():k4823. PubMed ID: 30518635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
    Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
    Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening.
    Kelly H; Mayaud P; Segondy M; Pant Pai N; Peeling RW
    Sex Transm Infect; 2017 Dec; 93(S4):S36-S45. PubMed ID: 29223961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: A systematic review and meta-analysis.
    Kelly H; Jaafar I; Chung M; Michelow P; Greene S; Strickler H; Xie X; Schiffman M; Broutet N; Mayaud P; Dalal S; Arbyn M; de Sanjosé S
    EClinicalMedicine; 2022 Nov; 53():101645. PubMed ID: 36187721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
    Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
    Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
    Arbyn M; Snijders PJ; Meijer CJ; Berkhof J; Cuschieri K; Kocjan BJ; Poljak M
    Clin Microbiol Infect; 2015 Sep; 21(9):817-26. PubMed ID: 25936581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
    Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
    Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study.
    Stanczuk GA; Currie H; Forson W; Baxter G; Lawrence J; Wilson A; Palmer T; Arbyn M; Cuschieri K
    Int J Cancer; 2022 Apr; 150(8):1350-1356. PubMed ID: 34850395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
    Leeman A; Del Pino M; Molijn A; Rodriguez A; Torné A; de Koning M; Ordi J; van Kemenade F; Jenkins D; Quint W
    BJOG; 2017 Aug; 124(9):1356-1363. PubMed ID: 28391609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.
    Virtanen E; Kalliala I; Dyba T; Nieminen P; Auvinen E
    Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
    Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
    Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.